AC Immune SA
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ACIU | PRTA | ALEC | PMN | ABOS | KRSA | |
|---|---|---|---|---|---|---|
| Market cap | 227.69M | 430.72M | 254.58M | 31.57M | 15.64M | 1.39B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 3.8 | -6.4 | -3.1 | -0.8 | -0.4 | -8.6 |
| Price/book | 4.3 | 1.5 | -25.6 | 0.6 | 0.5 | -3.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −33.62% | −16.77% | +75.38% | −63.90% | −88.47% | +160.90% |
| Today | +9.57% | +2.19% | +11.22% | +3.23% | −7.72% | −4.38% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ACIU news ›AC Immune Third Quarter 2026 Financial and Corporate Update
Gary Waanders, Ph.D., MBA Phone: +41 21 345 91 91 Nick Bastin, Joshua Evans, Aoife Minihan, Ben Cowe Phone: +44 (0) 20 4566 8543 AC Immune (NASDAQ: ACIU) is a clinical-stage biopharma company selectively targeting the key pathologic misfold
AC Immune director Graney reports 12,959 common shares
AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company developing precision immunotherapies and diagnostics for neurodegenerative diseases. - [Form 3] AC Immune SA Initial Statement of Beneficial Ownership AC Immune…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- manilatimes.net1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.